Agendia, based in Huntington Beach, CA, is a leading provider of genomic testing platforms that offer actionable insights for patients on their breast cancer journey. Their tests, including MammaPrint and BluePrint, help determine the likelihood of cancer recurrence and provide molecular subtyping for personalized treatment plans.
Founded by Prof. Laura van t Veer, a renowned figure in cancer diagnostics, Agendia is trusted by physicians and institutions worldwide for its proven results in matching patients to the right treatments at the right time. With a focus on improving quality of life and minimizing under- and over-treatment, Agendia's innovative approach to personalized medicine is shaping the future of breast cancer care.
Generated from the website